Cambridge, MA-based Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company’s discovery efforts target several disease areas, ocular diseases and engineered cell medicines are two such zones where its pipeline is most mature.

Editas has been traded publicly since February 2016. Currently, it has no marketed drug in its portfolio.

Editas recently underwent massive strategic reprioritization where it decided to discontinue internal investments in the company’s IRD programs, including EDIT-101 for Leber Congenital Amaurosis 10 (LCA10) and EDIT-103 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). Editas Medicine is currently looking for partnerships for the further development of its IRD programs.

It has also discontinued internal investments in the company’s wholly-owned multiplexed edited iPSC derived iNK cell programs, including EDIT-202 for solid tumors, looking for partnerships for the same as well.

In January 2023, Editas announced entering into a definitive agreement with Shoreline Biosciences to co-develop EDIT-202. In the same announcement, EDIT announced prioritizing EDIT-310 as their lead candidate for non-malignant hematologic diseases, such as severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

In August 2023, the company entered into a licensing agreement with Vor Bio, granting Vor Bio a non-exclusive license for the development of ex vivo Cas9 gene-edited hematopoietic stem cell (HSC) therapies for the treatment and/or prevention of hematological malignancies.

With no marketed products in its portfolio, Editas only generates collaborations and other research and development revenues. Editas generated total revenues of $20 million in 2022 compared with $26 million recorded in 2021.